As global markets continue to navigate the complexities of rising inflation and shifting trade policies, U.S. stock indexes are climbing toward record highs, with growth stocks outperforming value ...
With a sustained 7% annual growth rate, the CDMO sector reflects a fundamental shift in how modern medicines are brought to ...
Novo Nordisk alleges Singaporean biotech KBP Biosciences made misleading statements before the two firms inked a licensing ...
No improvement in overall survival (OS) was observed with palbociclib (Verzenio) plus endocrine therapy versus capecitabine ...
The growing global prevalence of influenza, mainly due to the transmission of the virus through droplets from coughing and sneezing, is the primary driver for the need for influenza vaccination.
AstraZeneca AZN stock has risen 8.6% in the past month, mainly due to mixed fourth-quarter results and a positive update from ...
A high omega-3, low omega-6 diet with fish oil led to a significant reduction in a biomarker for prostate cancer progression ...
In a Phase Ib trial, 71 percent of patients responded to zongertinib and lived a median six months before disease progression or death.
Since returning to office last month, U.S. President Donald Trump has initiated numerous tariffs and made even more frequent ...
Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...
The leading Extensive-Stage Small Cell Lung Cancer Companies such as Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback